argenx, FB102, Celiac Disease, Phase 2 Study, Clinical Trial Results, CD122 Inhibitor, Autoimmune Disease, Gluten Challenge, Intestinal Damage, Villus Height-to-Crypt Depth, IL-2, IL-15

AMSTERDAM, the Netherlands — October 8, 2026 argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, announced...